Guillaume Wallart, CEO, CellQuest explores how diagnostics models can make autologous cell therapy manufacturing work in our latest EPM online insight.
With more gene therapy trials securing approval and getting underway globally, innovators are focusing on developing viral vector carrier technologies that are safer and more predictable.
In our latest EPM Online Insight, Jim Sanford, Life Sciences Sector Strategy Manager, Watson-Marlow Fluid Technology Solutions explores how platform technologies enable the scale up of cell and gene therapy processing.
Dalip Sethi, Ph.D. and Joy Duemke, at Terumo Blood and Cell Technologies explore how automated apheresis platforms function as a therapeutic and an enabling technology for cell-based therapies.
Josh Ludwig, Global Commercial Director, ScaleReady explores the necessity of simplifying cell and gene therapy in order to successfully integrate artificial intelligence and automation technologies in our latest EPM insight.
Whether it’s cost-of-goods or build-versus-buy analysis, eXmoor Pharma’s Harvey Branton, Evelien Stalmeijer and Ruxandra Comisel say a clear understanding of the end goal is key to develop predictive models for cell and gene therapy manufacturing.
This article explores how starting materials, specifically producer cell lines and the design of transfer plasmids, affect the quality attributes of AAV vectors.
Justin Wilson, a partner and life sciences specialist at European intellectual property firm, Withers & Rogers explores why M&A are pushing to secure a slice of the gene therapy opportunity.
Natalia Elizalde PhD, Chief Business Development Officer, VIVEbiotech explores how the lentiviral vector specialists are bridging the gap between R&D and commercialisation.
Dr. Samir Acharya, Dr. Rajiv Vaidya and Cyrill Kellerhals from Andelyn Biosciences discuss the trends in the field of C> and explore the current and future challenges facing C> developers and manufacturers as well as solutions to overcome.
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc.
